NON-INVASIVE TREATMENT OPTIONS IN HYPERTROPHIC CARDIOMYOPATHY
|
|
- Donna Leonard
- 5 years ago
- Views:
Transcription
1 NON-INVASIVE TREATMENT OPTIONS IN HYPERTROPHIC CARDIOMYOPATHY SGK, 2015 Christiane Gruner University Heart Center, Zurich Department of Cardiology
2 NONINVASIVE TREATMENT OPTIONS: TOPICS 1. LVOT obstruction 2. microvascular dysfunction myocardial ischema 3. arrhythmias atrial fibrillation ventricular SCD
3 NONINVASIVE TREATMENT OPTIONS: BASIS 45 studies 2121 HCM patiens Spoladore R et al, EHJ, 2012;33:
4 NONINVASIVE TREATMENT OPTIONS: BASIS Spoladore R et al, EHJ, 2012;33:
5 NONINVASIVE TREATMENT OPTIONS: TOPICS 1. LVOT obstruction 2. microvascular dysfunction myocardial ischema 3. arrhythmias atrial fibrillation ventricular SCD
6 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION Septal hypertrophy Mitral valve anomalies Papillary muscle anomalies Geometry basis heart Contractility Drag forces SAM Mitral regurgitation LVOT obstruction
7 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION NEGATIVE CHRONOTROPE NEGATIVE INOTROPE BETA BLOCKERS DISOPYRAMIDE (VERAPAMIL) AHAACC Guidelines, Circulation 2011;124: ESC Guidelines, EHJ 2014;35(39):
8 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION NEGATIVE CHRONOTROPE NEGATIVE INOTROPE BETA BLOCKERS DISOPYRAMIDE (VERAPAMIL) AHAACC Guidelines, Circulation 2011;124: ESC Guidelines, EHJ 2014;35(39):
9 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION NEGATIVE CHRONOTROPE NEGATIVE INOTROPE BETA BLOCKERS DISOPYRAMIDE (VERAPAMIL) Class 1A antiarrhythmic, sodium channel blocker Negative inotrope In combination with beta blocker (prevent 1:1 conduction) QT interval prolongation check QT interval 7-10 days after initiation Anticholinergic side effects AHAACC Guidelines, Circulation 2011;124: ESC Guidelines, EHJ 2014;35(39):
10 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION NEGATIVE CHRONOTROPE NEGATIVE INOTROPE BETA BLOCKERS DISOPYRAMIDE (VERAPAMIL) AVOID ACE-inhibitors Nitro Volume depletion AHAACC Guidelines, Circulation 2011;124: ESC Guidelines, EHJ 2014;35(39):
11 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION PATIENT EXAMPLE: 44 YEARS OLD MALE No treatment, heart rate 95 bpm Bisoprolol 5mg od, disopyramide 100mg tid, heart rate 68 bpm
12 NONINVASIVE TREATMENT OPTIONS: LVOT OBSTRUCTION PATIENT EXAMPLE: 44 YEARS OLD MALE No treatment, heart rate 95 bpm Bisoprolol 5mg od, disopyramide 100mg tid, heart rate 68 bpm
13 NONINVASIVE TREATMENT OPTIONS: TOPICS 1. LVOT obstruction 2. microvascular dysfunction myocardial ischema 3. arrhythmias atrial fibrillation ventricular SCD
14 NONINVASIVE TREATMENT OPTIONS: MICROVASCULAR DYSFUNCTION Spoladore R et al, EHJ, 2012;33: Olivotto I, JACC, 2011;58(8): Olivotto I, JACC, 2006;47(5):1043-8
15 NONINVASIVE TREATMENT OPTIONS: MICROVASCULAR DYSFUNCTION SYMPTOMATIC HCM PATIENT LVEF <50% HEART FAILURE MANAGEMENT OBSTRUCTIVE PHYSIOLOGY YES NO SYSTOLIC LV FUNCTION BETA BLOCKER VERAPAMIL DRUGS SEA MYECTOMY LVEF 50% DIURETICS ACE INHIBITORS ARBs AHAACC Guidelines, Circulation 2011;124: ESC Guidelines, EHJ 2014;35(39):
16 NONINVASIVE TREATMENT OPTIONS: TOPICS 1. LVOT obstruction 2. microvascular dysfunction myocardial ischema 3. arrhythmias atrial fibrillation ventricular SCD
17 NONINVASIVE TREATMENT OPTIONS: ATRIAL FIBRILLATION LEFT ATRIAL SIZE FIBROSISSCARRING IN THE LEFT ATRIUM (SURGERIES) 25% of HCM PATIENTS
18 NONINVASIVE TREATMENT OPTIONS: ATRIAL FIBRILLATION RHYTHM CONTROL >>>>> RATE CONTROL DRUGS Beta blockers Calcium channel blockers (verapamil-type) Amiodarone, NO DRONEDARONE No class 1C anti-arrhythmic agents ELECTRIC DC CARDIOVERSION RELIEF OF LVOT OBSTRUCTION PULMONARY VEIN ISOLATION NO EXOTIC ANTI- ARRHYTHMIC AGENTS ORAL ANTICOAGULATION INDEPENDENT OF CHADS2Vasc SCORE
19 ATRIAL FIBRILLATION: RELIEF OF LVOT OBSTRUCTION PRE MYECTOMY POST MYECTOMY AHAACC Guidelines, Circulation 2011;124:
20 ATRIAL FIBRILLATION: PULMONARY VEIN ISOLATION overall lower success rate (50%) frequently: >1 intervention required Di Donna P et al, Europace, 2010;12:347-55
21 NONINVASIVE TREATMENT OPTIONS: VENTRICULAR ARRHYTHMIAS FIBROSISSCAR ISCHEMIA
22 NONINVASIVE TREATMENT OPTIONS: VENTRICULAR ARRHYTHMIAS
23 NONINVASIVE TREATMENT OPTIONS: VENTRICULAR ARRHYTHMIAS Maron BJ, JAMA 2002;287: Melacini P, Heart 2007;93:
24 NONINVASIVE TREATMENT OPTIONS: BASIS 217 patients 391 patients Spoladore R et al, EHJ, 2012;33:
25 NONINVASIVE TREATMENT OPTIONS: VENTRICULAR ARRHYTHMIAS RISK STRATIFICATION FOR SCD AHAACC Guidelines, Circulation 2011;124: ESC Guidelines, EHJ 2014;35(39):
26 NONINVASIVE TREATMENT OPTIONS: SUMMARY 1. LVOT OBSTRUCTION MEDICAL TREATMENT OPTIONS BETA BLOCKER +- DISOPYRAMIDE (VERAPAMIL) AVOID VOLUME DEPLETION AND DRUGS REDUCING AFTERLOAD AND PRELOAD INVASIVE PROCEDURES 2. MICROVASCULAR DYSFUNCTION BETA BLOCKER VERAPAMIL DIURETICS ACE INHIBITORS ARBs
27 NONINVASIVE TREATMENT OPTIONS: SUMMARY 3. ARRHYTHMIAS ATRIAL FIBRILLATION TRY TO ACHIEVE SINUS RHYTHM BETA BLOCKER AMIODARONE ORAL ANTICOAGULATION PULMONARY VEIN ISOLATION WITH LOWER SUCCESS RATE VENTRICULAR ARRHYTHMIAS NO MEDICAL THERAPY RISK STRATIFICATION FOR SCD AICD INSERTION
28 Thank you hypertrophic cardiomyopathy clinic
Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015
Steel vs Alcohol Or Neither Management of Hypertrophic Cardiomyopathy Josh Doll, MD January 24, 2015 47yo Male, Mr. L Severe progressive dyspnea on exertion and weight gain Previous avid Cross-Fit participant
More informationHypertrophic Cardiomyopathy: basics and management
Hypertrophic Cardiomyopathy: basics and management Bette Kim, MD Program Director, Cardiomyopathy Program Director, Roosevelt Hospital Echocardiography Lab Assistant Professor of Clinical Medicine Mount
More informationIndex of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125
145 Index of subjects A accessory pathways 3 amiodarone 4, 5, 6, 23, 30, 97, 102 angina pectoris 4, 24, 1l0, 137, 139, 140 angulation, of cavity 73, 74 aorta aortic flow velocity 2 aortic insufficiency
More informationTreatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD
Treatment of Hypertrophic Cardiomyopathy in 2017 Bruce B. Reid, MD Disclosures I have no conflicts of interest to disclose I will not be discussing any off label medications and/or devices Objectives 1)
More informationAnaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)
Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO) Dr. Siân Jaggar Consultant Anaesthetist Royal Brompton Hospital London UK Congenital Cardiac Services
More informationManaging Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology
Managing Hypertrophic Cardiomyopathy with Imaging Gisela C. Mueller University of Michigan Department of Radiology Disclosures Gadolinium contrast material for cardiac MRI Acronyms Afib CAD Atrial fibrillation
More informationHYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy
HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure Paolo Spirito, Genoa, Italy Clinical Substrates for Heart Failure Symptoms in HCM Diastolic dysfunction Atrial fibrillation LV outflow obstruction Evolution
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More information2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy Developed in Collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography,
More informationEtiology, Classification & Management. Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London
Etiology, Classification & Management Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London Introduction World Health Organization (1995): Diseases of myocardium (heart
More informationThe Management of Hypertrophic Cardiomyopathy
The Management of Hypertrophic Cardiomyopathy Evidence and Uncertainties Banff 2013 3058464-0 Management of HCM Key Elements Screen 1 relatives for HCM Serial Echo Genetic testing Assess risk for and prevent
More informationHypertrophic Cardiomyopathy
019-CardioCase:019-CardioCase 4/16/07 1:39 PM Page 19 Hypertrophic Cardiomyopathy Abdullah Alshehri, MD; and Andrew Ignaszewski, MD, FRCPC CardioCase presentation Presley s check-up Presley, 37, discovered
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationIn the Thick of It: Hypertrophic Cardiomyopathy
In the Thick of It: Hypertrophic Cardiomyopathy Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of Medicine Director, Heart Failure Outreach Department of Medicine, Division of Cardiology Advanced
More informationMedical management of AF: drugs for rate and rhythm control
Medical management of AF: drugs for rate and rhythm control Adel Khalifa Sultan Hamad, BMS, MD, FGHRS, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist Head of Electrophysiology
More informationThe Management of HOCM: What are the Surgical Options
The Management of HOCM: What are the Surgical Options Konstadinos A Plestis, MD System Chief of Cardiac Thoracic and Vascular Surgery Main Line Health Care System Professor Sidney Kimmel Medical College
More informationCardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition
Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition Table of Contents Volume 1 Chapter 1: Cardiovascular Anatomy and Physiology Basic Cardiac
More informationAlcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)?
Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)? Sarang Mangalmur+, MD Bryn Mawr Hospital, PA NCVH New Jersey 2015 Disclosures No relevant disclosures
More informationRest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome
Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome G. Deswarte, AS. Polge, N. Lamblin, A. Millaire, M. Richardson, C. Bauters,
More informationCardiomyopathy in Fabry s disease
Cardiomyopathy in Fabry s disease Herzinsuffizienzlunch Basel, 11.09.2018 Christiane Gruner Kardiologie, UniversitätsSpital Zürich Content Background / epidemiology Differential diagnosis Clinical presentations
More informationSurgical Myectomy for HOCM
Surgical Myectomy for HOCM Volkmar Falk Deutsches Herzzentrum Berlin Different Pathology of HOCM Impact on surgical strategy Said SM Expert Rev Cardiovasc Ther 2013 Different Pathology of HOCM Impact on
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationHOCM: Alcohol ablation or LVOT Surgery: When and what?
HOCM: Alcohol ablation or LVOT Surgery: When and what? Paul R Vogt/ Pascal A. Berdat Cardiovascular Center Zurich Clinic Im Park Zurich SKG/SGHC Annual Meeting, Zurich, 10.-12.6.15 ASA/Myectomy: Common
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationCatheter Ablation for AF: Patients, Procedures, Outcomes
Catheter Ablation for AF: Patients, Procedures, Outcomes John Sapp Director Heart Rhythm, QEII Health Sciences Centre Professor of Medicine, Dalhousie University Atrial Fibrillation Atrial Fibrillation
More informationInfluence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy
ORIGINAL ARTICLE 5 RAAS inhibitors should be avoided if possible in patients with obstructive HCM Influence of RAAS inhibition on outflow tract obstruction in hypertrophic cardiomyopathy Katrin Witzel,
More informationManagement of new-onset AF: Initial rate control treatment
Geneva Acute Crdiovascular Care Congress 2014 - October 18-20, 2014 Management of new-onset AF: Initial rate control treatment Antonio Raviele, MD, FESC, FHRS ALFA Alliance to Fight Atrial fibrillation,
More informationUse of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital
Use of Antiarrhythmic Drugs for AF Who, What and How? Dr. Marc Cheng Queen Elizabeth Hospital Content i. Rhythm versus Rate control ii. Anti-arrhythmic for Rhythm Control iii. Anti-arrhythmic for Rate
More informationHypertrophic Cardiomyopathy: Patient Management in 2018
Hypertrophic Cardiomyopathy: Patient Management in 2018 Mackram F. Eleid, MD Giornate Cardiologeche Torinesi October 26, 2018 2018 MFMER slide-1 Disclosures No relevant financial relationships to disclose
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationAtrial Fibrillation: Rate vs. Rhythm. Michael Curley, MD Cardiac Electrophysiology
Atrial Fibrillation: Rate vs. Rhythm Michael Curley, MD Cardiac Electrophysiology I have no relevant financial disclosures pertaining to this topic. A Fib Epidemiology #1 Most common heart rhythm disturbance
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationHypertrophic Cardiomyopathy: beyond gradient and wall thickness
Hypertrophic Cardiomyopathy: beyond gradient and wall thickness Michael H. Picard, M.D. Massachusetts General Hospital Harvard Medical School no disclosures special thanks to A. Baggish 1 Hypertrophic
More informationTachycardia-induced heart failure - Does it exist?
Tachycardia-induced heart failure - Does it exist? PD Dr Etienne Delacrétaz Clinique Cecil et Hôpital de Fribourg SSC Cardiology meeting 2015 Zürich Rapid atrial fibrillation is a common cause of heart
More informationIf you woke up breathing this morning, Congratulations! You get another chance. Use it wisely!
Seton Medical Center Austin, Texas Cynthia Webner DNP, RN, CCNS, CCRN-CMC, CHFN www.cardionursing.com RULES OF LIFE If you woke up breathing this morning, Congratulations! You get another chance. Use it
More informationJay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center
Jay Simonson, MD, FACC, FHRS Medical Director, Cardiac Electrophysiology Park Nicollet Heart and Vascular Center A-Fib Facts Yes, you may be able to blame your parents It is more of a nuisance than a
More informationLeft ventricular outflow tract obstruction: indications and limitations of current therapies
Left ventricular outflow tract obstruction: indications and limitations of current therapies Costas O Mahony Inherited Cardiovascular Diseases Unit, The Heart Hospital, London, UK. None to declare Conflicts
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationCardiomyopathy: The Good, the Bad.and the Insurable?
Cardiomyopathy: The Good, the Bad.and the Insurable? WAHLU Spring Seminar 2014 Joy Geiger, RN, BSN, ALMI Medical Consultant The Northwestern Mutual Life Insurance Company Milwaukee, WI Objectives Overview
More informationDegenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention
Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral
More informationHypertrophic Obstructive Cardiomyopathy
The new england journal of medicine clinical practice Hypertrophic Obstructive Cardiomyopathy Rick A. Nishimura, M.D., and David R. Holmes, Jr., M.D. This Journal feature begins with a case vignette highlighting
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationTreatment strategy decision tree
strategy decision tree strategy decision tree Confirmed diagnosis of AF Further investigations and clinical assessment including risk stratification for stroke/thromboembolism Paroxysmal AF Persistent
More informationIs cardioversion old hat? What is new in interventional treatment of AF symptoms?
Is cardioversion old hat? What is new in interventional treatment of AF symptoms? Joseph de Bono Consultant Electrophysiologist University Hospitals Birmingham Atrial Fibrillation (AF) Affects 2% of the
More informationCardiac Arrhythmias. Cathy Percival, RN, FALU, FLMI VP, Medical Director AIG Life and Retirement Company
Cardiac Arrhythmias Cathy Percival, RN, FALU, FLMI VP, Medical Director AIG Life and Retirement Company The Cardiovascular System Three primary functions Transport of oxygen, nutrients, and hormones to
More informationDysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias
Dysrhythmias Dysrythmias & Anti-Dysrhythmics Rhythm bad in the heart: Whitewater rafting Electrical impulses coordinate heart Reduction in Cardiac Output PEA Asystole Components of an ECG Wave EKG Parameters
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationDiastolic Heart Failure
Diastolic Heart Failure Presented by: Robert Roberts, M.D., FRCPC, MACC, FAHA, FRSC Professor of Medicine and Chair ISCTR University of Arizona, College of Medicine Phoenix Scientist Emeritus and Advisor,
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationGuideline pediatric congenital heart disease.
Guideline pediatric congenital heart disease www.kinderkardiologie.org/dgpkleitlinien.shtm Guideline primary cardiomyopathies Content Definition of primary cardiomyopathies Dilated cardiomyopathy Hypertrophic
More informationRhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014
Rhythm Control: Is There a Role for the PCP? Blake Norris, MD, FACC BHHI Primary Care Symposium February 28, 2014 Financial disclosures Consultant Medtronic 3 reasons to evaluate and treat arrhythmias
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationAtrial Fibrillation (AF)
Coronary Heart Disease Managed Clinical Network Atrial Fibrillation (AF) Guidelines for Primary Care Definition Atrial Fibrillation (AF) is defined as a cardiac arrhythmia with the following characteristics:
More informationThe 2014 Mayo Approach to the Management of HCM and Non-Compaction
The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1 Let
More informationArrhythmias (II) Ventricular Arrhythmias. Disclosures
Arrhythmias (II) Ventricular Arrhythmias Amy Leigh Miller, MD, PhD Cardiovascular Electrophysiology, Brigham & Women s Hospital Disclosures None Rhythms and Mortality Implantable loop recorder post-mi
More informationWhat s new in Hypertrophic Cardiomyopathy?
What s new in Hypertrophic Cardiomyopathy? Dr Andris Ellims HCM Clinic @ The Alfred Hypertrophic Cardiomyopathy = otherwise unexplained LV hypertrophy* 1 in 500 prevalence most common inherited cardiovascular
More informationAtrial Fibrillation and Heart failure
Atrial Fibrillation and Heart failure and a bit about anticoagulation Tim Sutton, Consultant Cardiologist Middlemore Hospital, Manukau City and Auckland Heart Group Why Does AF Cause Heart Failure Impaired
More informationANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar
ANTI-ARRHYTHMICS AND WARFARIN Dr Nithish Jayakumar Contents 1. Anti-arrhythmics Pacemaker and myocardial potentials Drug classes mechanisms; s/e; contra-indications Management of common arrhythmias 2.
More information3/25/2017. Program Outline. Classification of Atrial Fibrillation
Alternate Strategies to Antiarrhythmic Therapy: The Role of Ablation Jennifer El Aile, MS, AGPCNP-BC Electrophysiology Nurse Practitioner Clinical Lecturer at the University of Michigan Program Outline
More informationManagement of Atrial Fibrillation in Heart Failure
Management of Atrial Fibrillation in Heart Failure Hani Sabbour MD FACC FHRS FASE Clinical Assistant Professor of Cardiology Brown University, Warren Alpert School of Medicine Rhode Island, USA Consultant
More informationΜαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό
Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling
More informationCongestive Heart Failure or Heart Failure
Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationAtrialfibrillation. Assoc. Prof. Lucie Riedlbauchová, MD, PhD Department of Cardiology University hospital in Motol
Atrialfibrillation Assoc. Prof. Lucie Riedlbauchová, MD, PhD Department of Cardiology University hospital in Motol ESC guidelines for the management of atrial fibrillation Epidemiology Prevalence 1-2%
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationHeart failure for syndicate
Heart failure for syndicate By M.Wafaie Aboleineen,MD,FACC ESC Guidelines for the diagnosis and treatment of heart failure Part I 1 4 2 Common ECG abnormalities in HF 3 Common CXR abnormalities in HF Common
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More informationHypertrophic Cardiomyopathy Ud Din Shah, MD; DM; FICC; FESC; FACC
3 Article 1 Physicians Academy January 2018 Hypertrophic Cardiomyopathy Mehraj Ud Din Shah, MD; DM; FICC; FESC; FACC Hypertrophic Cardiomyopathy (HCM) is a genetic disorder which causes clinically unexplained
More informationEHRA/EUROPACE 2011 Madrid, Spain June
EHRA/EUROPACE 2011 Madrid, Spain June 26.-29.2011 Implementing modern management in atrial fibrillation patients Proceedings from the 3rd AFNet/EHRA consensus conference EHRA Special Session Different
More informationDiastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure
Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationESC Guidelines on Hypertrophic Cardiomyopathy
2014 version ES Guidelines on Hypertrophic ardiomyopathy Pr Michel KOMAJDA Dept of ardiology HU PTE SALPETRERE University Pierre et Marie urie PARS FRANE European Heart Journal (2014):doi:10.1093/eurheartj/ehu284
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationCASE DISCUSSION. Dr JAYASREE VEERABOINA 2nd yr PG MS OBG
CASE DISCUSSION Dr JAYASREE VEERABOINA 2nd yr PG MS OBG Normal Cardiovascular changes in Pregnancy CARDIAC OUTPUT 5 th wk -- starts 12 wks -- 30-35% 30-32 wks -- 40% During labour -- 50% After delivery
More informationEchocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016
Echocardiographic Evaluation of the Cardiomyopathies Stephanie Coulter, MD, FACC, FASE April, 2016 Cardiomyopathies (CMP) primary disease intrinsic to cardiac muscle Dilated CMP Hypertrophic CMP Infiltrative
More informationEffect of Septal Ablation on Myocardial Relaxation and Left Atrial Pressure in Hypertrophic Cardiomyopathy
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 5, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.07.004 Effect of
More informationTake-home Messages from Recent Heart Failure Trials: Heart Rate as a Target
Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target JEFFREY S. BORER, M.D. Professor and Chairman, Department of Medicine and Chief, Division of Cardiovascular Medicine; Director,
More informationCardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center
Cardiac Issues in the Adolescent Athlete Sean Levchuck, M.D. St. Francis Hospital- The Heart Center Sudden Cardiac Death Incidence is.6-6.2 % per 100,000 children in the US 20-25 % of the deaths occur
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More information9/17/2010. Phidippides. Phidippides. Sudden Death in the Young Athlete. What is the extent of the problem? Can we prevent it?
Phidippides Phidippides Sudden Death in the Young Athlete What is the extent of the problem? Can we prevent it? 1 Number of cardiovascular (CV), trauma-related, and other sudden death events in 1866 young
More informationCardiomyopathy. Cardiomyopathies HOCM. Hypertrophic Obstructive Cardiomyopathy. Systolic Anterior Movement (SAM) of Mitral Valve (Venturi Effect) Cine
Jens Bremerich Radiology University Hospital Basel Hypertrophic Obstructive Cine VENC Cine (5m/s) Modified Bernoulli Equation: P (in mmhg) = 4 x (Vmax)2 Vmax= 4.2 m/s, P = 70mm Hg Hydrodynamica 738 HOCM
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,
More informationCommon Codes for ICD-10
Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified
More informationStress Testing in Valvular Disease
2017 ASE Florida Orlando, FL October 10, 2017 2:40 2:50 PM 10 min Grand Harbor Ballroom South Stress Testing in Valvular Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationThe pill-in-the-pocket strategy for paroxysmal atrial fibrillation
The pill-in-the-pocket strategy for paroxysmal atrial fibrillation KONSTANTINOS P. LETSAS, MD, FEHRA LABORATORY OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL OF ATHENS ARRHYTHMIAS UPDATE,
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationCardiomyopathies. Andre Keren, MD
Cardiomyopathies Andre Keren, MD Cardiomyopathies Heart muscle disease of unknown etiology Elliott P et al. Eur Heart J 2008;29:270-276 Definition of Cardiomyopathies Elliott P et al. Eur Heart J 2008;29:270-276
More informationBasic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function
Basic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function J A F E R A L I, M D U N I V E R S I T Y H O S P I T A L S C A S E M E D I C A L C E N T E R S T A F F C A R D I O T
More information